Das Speichelgangkarzinom der Glandula Sublingualis

Sartorius, Céline Montavon; Gille, F.; Bédrossian-Pfingsten, J.; Kempf, H.-G.

doi:10.1055/s-2005-921217

Cited by 11 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of them are adenoid cystic carcinoma (ACC), even though some scholars also reported rare tumors such as mucinous adenocarcinoma [2], papillary cystadenocarcinoma [3], polymorphous low-grade adenocarcinoma [4], salivary duct carcinoma [5] and acinic cell carcinoma [6]. …”

Section: Introductionmentioning

confidence: 99%

Malignant Sublingual Gland Tumors: A Retrospective Clinicopathologic Study of 28 Cases

Gao

Wang

et al. 2007

Oncology

View full text Add to dashboard Cite

Objectives: To evaluate the clinicopathologic features and therapeutic efficacy of malignant sublingual gland tumors. PatientsandMethods: From 1955 to 2005, the clinicopathologic data of 28 patients treated in our hospital were obtained from their medical records and histopathologic slides. Results: There were 16 males and 12 females, with a mean age of 50.3 years. Eighteen cases (64.3%) were adenoid cystic carcinoma; 16 (57.1%) cases were clinically staged as III–IV. Adenoid cystic carcinoma was mainly of the histologic type, and the other histologic classifications included mucoepidermoid carcinoma, myoepithelial carcinoma, polymorphous low-grade adenocarcinoma, adenocarcinoma and malignant pleomorphic adenoma. Pulmonary metastasis and tumor recurrence were the main death reasons. Eleven patients remain alive and well 34–312 months (median 108) after treatment. Conclusions: Malignant sublingual gland tumors are extremely rare and most are adenoid cystic carcinoma. Surgery is the main treatment option. For adenoid cystic carcinoma, hematogenous spread is common, and pulmonary metastasis is a common pathway of the distant metastasis. For some patients having lung metastasis, regional control is also important as there are some examples of patients surviving many years with asymptomatic pulmonary metastases. Postoperative radiation therapy may be adjuvant for selected patients with high-stage and high-grade tumors, or when there is concern about the inadequacy of the resection. The effect of chemotherapy remains elusive.

show abstract

Section: Introductionmentioning

confidence: 99%

Malignant Sublingual Gland Tumors: A Retrospective Clinicopathologic Study of 28 Cases

Gao

Wang

et al. 2007

Oncology

View full text Add to dashboard Cite

show abstract

“…This neoplasm accounts for ~10% of malignant tumors of the salivary glands, whether de novo or ex-pleomorphic adenoma, and has a poor prognosis (<45% 5 y survival). It involves most commonly the parotid gland but can occur also in the submandibular and sublingual gland, minor salivary gland, larynx, and sinonasal tract 1–6…”

mentioning

confidence: 99%

“…It involves most commonly the parotid gland but can occur also in the submandibular and sublingual gland, minor salivary gland, larynx, and sinonasal tract. [1][2][3][4][5][6] This malignancy shows strong immunophenotypic and morphologic overlap with in situ and invasive ductal breast carcinoma. 7 Microscopically, it is characterized by variably sized, rounded to irregular, solid or cystic nodules of tumor cells, often with conspicuous comedonecrosis.…”

mentioning

confidence: 99%

PAX-8 Expression in Salivary Duct Carcinoma

Serinelli

Mirchia²,

Gitto³

et al. 2021

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

Salivary duct carcinoma (SDC) is a high-grade adenocarcinoma resembling breast ductal carcinoma. It accounts for ~10% of malignant tumors of the salivary glands. Most cases show expression of CK7 and androgen receptor. PAX-8 is a transcription factor, with expression reported in renal, Müllerian, and thyroid carcinomas. Previous studies have described an absence of PAX-8 immunostaining in most primary salivary gland neoplasms, including SDCs. However, PAX-8 expression is frequently found in neoplasms that can metastasize to salivary glands, suggesting the possibility that this protein can be used to differentiate SDC from secondary neoplastic involvement of the salivary gland. We evaluated the expression of PAX-8 in 14 cases of SDC from our institution. One case showed diffuse moderate to strong PAX-8 positivity, while 2 tumors showed focal weak staining. Therefore, we conclude that although the majority of SDC are negative for PAX-8, rare diffuse positivity can be seen in these primary salivary gland tumors. This could potentially pose difficulty in ruling out metastatic disease from another PAX-8-positive primary neoplasm.

show abstract

“…A total of 85% of the cases occur in the parotid gland, followed by the submandibular gland (approximately 8% of cases) [1]. A single case was reported with an arising of the sublingual gland [2]. Among all salivary gland tumors, the incidence of SDC is 1-3% [1].…”

Section: Introductionmentioning

confidence: 99%

Long-Term Recurrence-Free Survival After Salivary Duct Carcinoma of the Parotid: A 10-Year Follow-Up Case Report

Schneider¹,

Kämmerer²

2020

SCR

View full text Add to dashboard Cite

Salivary duct carcinoma (SDC) represents a very rare and aggressive parotid neoplasm. A 70-year-old male was admitted to the hospital with a swelling of the right parotid region, persisting for twelve weeks. Based on sonography and contrast-enhanced computed tomography, a suspicious lesion showing mass expansion and invasion of surrounding tissues was seen. Intraoperative biopsy brought evidence of SDC. In accordance, surgical treatment included parotidectomy with preservation of the facial nerve as well as ipsilateral neck dissection due to suspicious lymphatic nodes. Afterwards, an adjuvant radiation therapy was undertaken. At 10 years of follow-up, the patient was alive and free of recurrence with full function of the facial nerve. In conclusion, keeping in mind its poor prognosis, the rare parotid salivary duct carcinoma needs aggressive therapy consisting of a surgical as well as a radiation therapy approach.

show abstract

Das Speichelgangkarzinom der Glandula Sublingualis

Abstract: A rare case of a salivary duct carcinoma of sublingual salivary gland origin is presented. Usually the prognosis is poor. The adequate therapy is the complete surgical extirpation including the surgery of the regional lymphatic nodes and the additional radiotherapy.

Cited by 11 publications

References 4 publications

Malignant Sublingual Gland Tumors: A Retrospective Clinicopathologic Study of 28 Cases

Malignant Sublingual Gland Tumors: A Retrospective Clinicopathologic Study of 28 Cases

PAX-8 Expression in Salivary Duct Carcinoma

Long-Term Recurrence-Free Survival After Salivary Duct Carcinoma of the Parotid: A 10-Year Follow-Up Case Report

Contact Info

Product

Resources

About